布比卡因脂质体与罗哌卡因在肌间沟入路臂丛神经阻滞中的术后镇痛效果评价:随机对照试验

注册号:

Registration number:

ChiCTR2500112232 

最近更新日期:

Date of Last Refreshed on:

2025-11-11 17:11:44 

注册时间:

Date of Registration:

2025-11-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体与罗哌卡因在肌间沟入路臂丛神经阻滞中的术后镇痛效果评价:随机对照试验

Public title:

Evaluation of postoperative analgesic effects of liposomal bupivacaine and ropivacaine in Interscalene brachial plexus block: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体与罗哌卡因在肌间沟入路臂丛神经阻滞中的术后镇痛效果评价:随机对照试验

Scientific title:

Evaluation of postoperative analgesic effects of liposomal bupivacaine and ropivacaine in Interscalene brachial plexus block: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

唐倩倩 

研究负责人:

王长明 

Applicant:

Qianqian Tang 

Study leader:

Changming Wang 

申请注册联系人电话:

Applicant telephone:

+86 178 6653 3118

研究负责人电话:

Study leader's
telephone:

+86 177 0248 6100

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

3197785219@qq.com

研究负责人电子邮件:

Study leader's E-mail:

teamwangcm@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市沈河区文艺路33号

研究负责人通讯地址:

辽宁省沈阳市沈河区文艺路33号

Applicant address:

33 Wenyi Road, Shenhe District, Shenyang, Liaoning

Study leader's address:

33 Wenyi Road, Shenhe District, Shenyang, Liaoning

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

辽宁省人民医院

Applicant's institution:

Liaoning Provincial People's Hospital

研究负责人所在单位:

辽宁省人民医院

Affiliation of the Leader:

Liaoning Provincial People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)H044号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

辽宁省人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Liaoning Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-10 00:00:00

伦理委员会联系人:

郑凯

Contact Name of the ethic committee:

Kai Zheng

伦理委员会联系地址:

辽宁省沈阳市沈河区文艺路33号

Contact Address of the ethic committee:

33 Wenyi Road, Shenhe District, Shenyang, Liaoning

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 24 2401 6585

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

辽宁省人民医院

Primary sponsor:

Liaoning Provincial People's Hospital

研究实施负责(组长)单位地址:

辽宁省沈阳市沈河区文艺路33号

Primary sponsor's address:

33 Wenyi Road, Shenhe District, Shenyang, Liaoning

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

辽宁省人民医院

具体地址:

辽宁省沈阳市沈河区文艺路33号

Institution
hospital:

Liaoning Provincial People's Hospital

Address:

33 Wenyi Road, Shenhe District, Shenyang, Liaoning

经费或物资来源:

Source(s) of funding:

None

研究疾病:

肩袖损伤  

Target disease:

Rotator Cuff Injury

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较超声引导下肌间沟臂丛神经阻滞使用布比卡因脂质体与罗哌卡因对肩关节镜手术患者的术后镇痛效果,旨在为临床使用提供参考。  

Objectives of Study:

Comparing the postoperative analgesic effects of interscalene brachial plexus block using liposomal bupivacaine and ropivacaine under ultrasound guidance on patients undergoing shoulder arthroscopy surgery, with the aim of providing reference for clinical use.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

拒绝参与,手术部位感染,现有解剖异常,对研究药物过敏史,周围神经存在病变,肌肉骨骼和桡神经或尺神经病变,精神障碍,凝血功能障碍,BMI>35 kg/m^2,严重肺部疾病,心功能不全,脑血管疾病,肝功能障碍,严重肾功能不全,孕妇或哺乳期妇女,长期使用阿片类药物者以及近期3个月之内参与过其他临床试验者。

Exclusion criteria:

Refusal to participate, surgical site infection, existing anatomical abnormalities, history of drug allergies to research drugs, peripheral nerve lesions, musculoskeletal and radial or ulnar nerve lesions, mental disorders, coagulation dysfunction, BMI>35 kg/m^2, Severe lung disease, heart failure, cerebrovascular disease, liver dysfunction, severe renal dysfunction, pregnant or lactating women, long-term use of opioid drugs, and those who have participated in other clinical trials within the past 3 months.

研究实施时间:

Study execute time:

From 2025-11-01 00:00:00 To 2027-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-01 00:00:00 To 2027-03-31 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

39

Group:

Group A

Sample size:

干预措施:

10 ml 布比卡因脂质体原液(133mg)+2 ml 0.9%生理盐水

干预措施代码:

Intervention:

10 ml of liposomal bupivacaine solution (133mg)+2 ml of 0.9% saline solution

Intervention code:

组别:

B组

样本量:

39

Group:

Group B

Sample size:

干预措施:

0.5%罗哌卡因12ml

干预措施代码:

Intervention:

0.5% ropivacaine 12ml

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

辽宁省人民医院 

单位级别:

三甲 

Institution
hospital:

Liaoning Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

患者NRS疼痛评分

指标类型:

主要指标

Outcome:

Patient NRS pain score

Type:

Primary indicator

测量时间点:

术后6小时,术后12小时,术后24小时,术后48小时和术后72小时

测量方法:

Measure time point of outcome:

6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after surgery

Measure method:

指标中文名:

感觉阻滞的持续时间

指标类型:

次要指标

Outcome:

Duration of sensory

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动阻滞的持续时间

指标类型:

次要指标

Outcome:

Duration of motor block

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72h内镇痛药物的需求

指标类型:

次要指标

Outcome:

Demand for analgesics within 72 hours after operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心呕吐发生率

指标类型:

次要指标

Outcome:

The incidence of postoperative nausea and vomiting

Type:

Secondary indicator

测量时间点:

术后6小时,术后12小时,术后24小时,术后48小时和术后72小时

测量方法:

Measure time point of outcome:

6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after surgery

Measure method:

指标中文名:

收缩压

指标类型:

次要指标

Outcome:

Systolic pressure

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

Diastolic pressure

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

Mean arterial pressure

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

指标中文名:

血氧饱和度

指标类型:

次要指标

Outcome:

Oxygen saturation

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

指标中文名:

脑电双频指数

指标类型:

次要指标

Outcome:

BIS

Type:

Secondary indicator

测量时间点:

入室时,ISBPB后1分钟,全麻后1分钟,全麻后15分钟,全麻后30分钟和离室前1分钟

测量方法:

Measure time point of outcome:

When entering the room, 1 minute after ISBPB, 1 minute after general anesthesia, 15 minutes after general anesthesia, 30 minutes after general anesthesia, and 1 minute before leaving the room

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者使用SPSS25.0软件对78例患者进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers used spss25.0 software to randomly divide 78 patients.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本试验为双盲试验,所有参与本研究的患者、数据收集者和分析人员、外科医生对治疗分配一无所知。

Blinding:

This was a double-blind trial and all patients, data collectors and analysts, and surgeons involved in this study had no knowledge of the treatment assignment.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心,www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China clinical trial registration center, www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-11 17:11:27